Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:APGENYSE:DNANASDAQ:GLPGNASDAQ:RXRX On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAPGEApogee Therapeutics$41.96+1.9%$38.38$26.20▼$63.50$1.93B1.38553,167 shs637,466 shsDNAGinkgo Bioworks$8.53-0.5%$7.78$5.00▼$17.46$501.62M1.251.46 million shs987,316 shsGLPGGalapagos$27.42-2.8%$27.23$22.36▼$31.23N/A0.07249,946 shs322,509 shsRXRXRecursion Pharmaceuticals$5.03-1.6%$4.92$3.79▼$12.36$2.04B0.8415.42 million shs32.01 million shs7 Stocks to Buy And Hold ForeverEnter your email address and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising. Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAPGEApogee Therapeutics0.00%-5.67%+3.96%+5.32%+15.37%DNAGinkgo Bioworks0.00%-4.54%+24.44%+16.81%-59.64%GLPGGalapagos0.00%-4.66%-4.73%+6.20%+6.11%RXRXRecursion Pharmaceuticals0.00%+2.24%+21.50%-24.70%-48.14%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationAPGEApogee Therapeutics2.1785 of 5 stars3.51.00.00.01.54.20.0DNAGinkgo Bioworks0.8538 of 5 stars0.81.00.00.03.12.51.3GLPGGalapagos0.1844 of 5 stars0.82.00.00.01.30.00.6RXRXRecursion Pharmaceuticals1.8294 of 5 stars3.21.00.00.02.61.70.6Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceAPGEApogee Therapeutics 3.00Buy$94.60125.45% UpsideDNAGinkgo Bioworks 1.67Reduce$5.77-32.42% DownsideGLPGGalapagos 1.50Reduce$25.33-7.61% DownsideRXRXRecursion Pharmaceuticals 2.33Hold$7.0039.17% UpsideCurrent Analyst Ratings BreakdownLatest DNA, GLPG, APGE, and RXRX Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails6/16/2025RXRXRecursion PharmaceuticalsMorgan StanleySubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetEqual Weight ➝ Equal Weight$8.00 ➝ $5.005/6/2025RXRXRecursion PharmaceuticalsNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$11.00 ➝ $8.004/10/2025RXRXRecursion PharmaceuticalsMorgan StanleySubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetEqual Weight ➝ Equal Weight$10.00 ➝ $8.004/8/2025RXRXRecursion PharmaceuticalsNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$11.00 ➝ $11.00(Data available from 6/22/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookAPGEApogee TherapeuticsN/AN/AN/AN/A$15.92 per shareN/ADNAGinkgo Bioworks$227.04M2.20N/AN/A$13.17 per share0.65GLPGGalapagos$298.31MN/A$0.73 per share37.76$47.57 per shareN/ARXRXRecursion Pharmaceuticals$58.84M34.75N/AN/A$2.61 per share1.93Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateAPGEApogee Therapeutics-$182.15M-$3.60N/AN/AN/AN/A-28.35%-26.98%8/11/2025 (Estimated)DNAGinkgo Bioworks-$547.03M-$9.16N/AN/AN/A-198.84%-52.35%-27.14%8/14/2025 (Estimated)GLPGGalapagos$80.16MN/A0.00N/AN/AN/AN/AN/A7/23/2025 (Estimated)RXRXRecursion Pharmaceuticals-$463.66M-$1.77N/AN/AN/A-961.32%-74.70%-54.02%8/6/2025 (Estimated)Latest DNA, GLPG, APGE, and RXRX EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/12/2025Q1 2025APGEApogee Therapeutics-$1.19-$0.95+$0.24-$0.95N/AN/A5/6/2025Q1 2025DNAGinkgo Bioworks-$1.23-$1.58-$0.35-$1.68$38.70 million$48.32 million5/5/2025Q1 2025RXRXRecursion Pharmaceuticals-$0.44-$0.50-$0.06-$0.50$18.12 million$14.75 million4/23/2025Q1 2025GLPGGalapagos-$0.23-$2.47-$2.24-$2.45$72.22 million$97.33 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthAPGEApogee TherapeuticsN/AN/AN/AN/AN/ADNAGinkgo BioworksN/AN/AN/AN/AN/AGLPGGalapagosN/AN/AN/AN/AN/ARXRXRecursion PharmaceuticalsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioAPGEApogee TherapeuticsN/A15.8215.82DNAGinkgo BioworksN/A4.884.88GLPGGalapagosN/A7.957.86RXRXRecursion Pharmaceuticals0.024.114.11Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipAPGEApogee Therapeutics79.04%DNAGinkgo Bioworks78.63%GLPGGalapagos32.46%RXRXRecursion Pharmaceuticals89.06%Insider OwnershipCompanyInsider OwnershipAPGEApogee Therapeutics42.77%DNAGinkgo Bioworks9.72%GLPGGalapagos2.91%RXRXRecursion Pharmaceuticals8.43%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableAPGEApogee Therapeutics9146.05 million26.35 millionOptionableDNAGinkgo Bioworks64058.53 million52.84 millionOptionableGLPGGalapagos1,310N/AN/AOptionableRXRXRecursion Pharmaceuticals400406.49 million372.23 millionOptionableDNA, GLPG, APGE, and RXRX HeadlinesRecent News About These CompaniesRecursion Pharmaceuticals (RXRX) Declines More Than Market: Some Information for InvestorsJune 20 at 6:51 PM | zacks.comRecursion Pharmaceuticals, Inc. (NASDAQ:RXRX) Position Boosted by SG Americas Securities LLCJune 20 at 3:28 AM | marketbeat.comRecursion Pharmaceuticals (NASDAQ:RXRX) Shares Up 5.6% - Here's What HappenedJune 19 at 11:50 AM | marketbeat.comRecursion Pharmaceuticals (NASDAQ:RXRX) Stock Price Up 6.5% - Time to Buy?June 18, 2025 | marketbeat.comRecursion Pharmaceuticals (NASDAQ:RXRX) Given New $5.00 Price Target at Morgan StanleyJune 17, 2025 | americanbankingnews.comExpert Outlook: Recursion Pharmaceuticals Through The Eyes Of 4 AnalystsJune 17, 2025 | benzinga.comMorgan Stanley Lowers Recursion Pharmaceuticals (NASDAQ:RXRX) Price Target to $5.00June 16, 2025 | marketbeat.comIs This Beaten-Down Cathie Wood Artificial Intelligence (AI) Stock a Buy?June 16, 2025 | fool.comLeerink Partnrs Issues Positive Estimate for RXRX EarningsJune 15, 2025 | americanbankingnews.comRecursion Pharmaceuticals (NASDAQ:RXRX) Trading Down 2.2% - Here's WhyJune 13, 2025 | marketbeat.comLeerink Partnrs Has Positive Estimate for RXRX Q2 EarningsJune 13, 2025 | marketbeat.comRecursion Pharmaceuticals (NASDAQ:RXRX) Stock Price Down 2.4% - Should You Sell?June 12, 2025 | marketbeat.comRecursion Pharmaceuticals (NASDAQ:RXRX) Trading 4% Higher - Should You Buy?June 11, 2025 | marketbeat.comInsmed surges on lung drug data; Recursion cuts staffJune 11, 2025 | biopharmadive.comAI-Focused Recursion Pharmaceuticals Stock Jumped 31% Last Week; Here's Why June 11, 2025 | talkmarkets.comRecursion to lay off 20% of workforce amid biotech funding woesJune 11, 2025 | msn.comRecursion: Lack Of Near-Term Catalysts Leaves The Stock VulnerableJune 11, 2025 | seekingalpha.comRecursion lays off 20% of staff in wake of pipeline cutbacksJune 10, 2025 | fiercebiotech.comRecursion Pharmaceuticals Stock Is Up 10% Today: What's Happening?June 10, 2025 | benzinga.comRecursion Pharmaceuticals: Recent Readouts Disappointing, Future Readouts RiskyJune 10, 2025 | seekingalpha.comRecursion Pharma to reduce workforce by 20%June 10, 2025 | msn.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeDNA, GLPG, APGE, and RXRX Company DescriptionsApogee Therapeutics NASDAQ:APGE$41.96 +0.78 (+1.89%) Closing price 06/20/2025 04:00 PM EasternExtended Trading$42.02 +0.05 (+0.13%) As of 06/20/2025 07:22 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Apogee Therapeutics, Inc., through its subsidiary, operates as a biotechnology company that develops biologics for the treatment of atopic dermatitis (AD), asthma, chronic obstructive pulmonary disease (COPD), and related inflammatory and immunology indications. The company primarily develops APG777, a subcutaneous (SQ) extended half-life monoclonal antibody (mAb) for AD; and APG808, an SQ extended half-life mAb for COPD. Its earlier-stage programs comprise APG990, an SQ extended half-life mAb for the treatment of AD; and APG222, an extended half-life SQ antibodies for AD. Apogee Therapeutics, Inc. was incorporated in 2022 and is headquartered in Waltham, Massachusetts.Ginkgo Bioworks NYSE:DNA$8.53 -0.05 (-0.55%) Closing price 06/20/2025 03:59 PM EasternExtended Trading$8.37 -0.16 (-1.91%) As of 06/20/2025 07:52 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Ginkgo Bioworks Holdings, Inc., together with its subsidiaries, develops platform for cell programming in the United States. Its platform is used to program cells to enable biological production of products, such as novel therapeutics, food ingredients, and chemicals derived from petroleum. It serves pharma and biotech, agriculture, industrial and environment, food and nutrition, consumer and technology, and government and defense industries. Ginkgo Bioworks Holdings, Inc. was founded in 2008 and is headquartered in Boston, Massachusetts.Galapagos NASDAQ:GLPG$27.42 -0.80 (-2.83%) Closing price 06/20/2025 04:00 PM EasternExtended Trading$27.42 0.00 (0.00%) As of 06/20/2025 05:03 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Galapagos NV, a biotechnology company, develops medicines focusing on oncology and immunology primarily in the United States and Europe. The company's pipeline products comprise GLPG3667 that has completed phase 1b trial; GLPG5101, a CD19 CAR-T product candidate manufactured at point-of-care, currently in Phase1/2 trial in relapsed/refractory non-hodgkin lymphoma; GLPG5201, a CD19 CAR-T product candidates manufactured at point-of-care, currently in phase 1/2 trial in replapsed/refractory chronic lymphocytic leukemia; and GLPG5301, a BCMA CAR-T product candidate manufactured at point-of-care, currently in phase 1/2 in relapsed/refractory multiple myeloma. The company has collaboration agreements with Gilead Sciences, Inc.; and AbbVie S.à r.l. Galapagos NV was incorporated in 1999 and is headquartered in Mechelen, Belgium.Recursion Pharmaceuticals NASDAQ:RXRX$5.03 -0.08 (-1.57%) Closing price 06/20/2025 04:00 PM EasternExtended Trading$5.02 -0.01 (-0.18%) As of 06/20/2025 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Recursion Pharmaceuticals, Inc. operates as a clinical-stage biotechnology company, engages in the decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery. The company develops REC-994, which is in Phase 2 clinical trial to treat cerebral cavernous malformation; REC-2282, which is in Phase 2/3 clinical trial for the treatment of neurofibromatosis type 2; REC-4881, which is in Phase 1b/2 clinical trial to treat familial adenomatous polyposis; REC-3964, which is in Phase 1 clinical trial to treat Clostridioides difficile infection; and REC-4881, which is in Phase 2 clinical trial to treat AXIN1 or APC mutant cancers. Its preclinical stage product includes RBM39 to treat HR-proficient ovarian cancer. The company has collaboration and agreement with Bayer AG; the University of Utah Research Foundation; Ohio State Innovation Foundation; Roche & Genentech; and Takeda Pharmaceutical Company Limited. Recursion Pharmaceuticals, Inc. was incorporated in 2013 and is headquartered in Salt Lake City, Utah. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas New All-Time Highs Coming for Broadcom? Wall Street Says Yes Smith & Wesson Stock Falls on Earnings Miss, Tariff Woes Marvell's New AI Chip Deals Capture Wall Street’s Attention Super Micro Computer Stock's Rally Backed by Strong Financials Forget the Fed: Home Depot Is the Real Gauge of the U.S. Consumer GE Aerospace Turns Engines Into Long-Term Profits 3 Reasons AMD Could Be the Hottest Stock of the Summer Analysts Keep Boosting Taiwan Semiconductor Stock—Here's Why Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
